All Title Author
Keywords Abstract

PLOS ONE  2012 

MicroRNA-149 Inhibits Proliferation and Cell Cycle Progression through the Targeting of ZBTB2 in Human Gastric Cancer

DOI: 10.1371/journal.pone.0041693

Full-Text   Cite this paper   Add to My Lib

Abstract:

An increasing body of evidence indicates that miR-149 can both suppress and promote tumor growth depending on the tumor type. However, the role of miR-149 in the progression of gastric cancer (GC) remains unknown. Here we report that miR-149 is a tumor suppressor in human gastric cancer. miR-149 expression is decreased in GC cell lines and clinical specimens in comparison to normal gastric epithelial cell and tissues, respectively. The expression levels of miR-149 also correlate with the differentiation degree of GC cells and tissues. Moreover, ectopic expression of miR-149 in gastric cancer cells inhibits proliferation and cell cycle progression by down-regulating ZBTB2, a potent repressor of the ARF-HDM2-p53-p21 pathway, with a potential binding site for miR-149 in its mRNA's 3′UTR. It is also found that ZBTB2 expression increases in GC cells and tissues compared to normal gastric epithelial cell and tissues, respectively. Silencing of ZBTB2 leads to suppression of cell growth and cell cycle arrest in G0/G1 phase, indicating that ZBTB2 may act as an oncogene in GC. Furthermore, transfection of miR-149 mimics into gastric cancer cells induces down-regulation of ZBTB2 and HDM2, and up-regulation of ARF, p53, and p21 compared to the controls. In summary, our data suggest that miR-149 functions as a tumor suppressor in human gastric cancer by, at least partially through, targeting ZBTB2.

References

[1]  Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA: a cancer journal for clinicians. CA Cancer J Clin 61: 69–90.
[2]  Correa P (1992) Human gastric carcinogenesis: a multistep and multifactorial process—first American Cancer Society award lecture on cancer epidemiology and prevention. Cancer research 52: 6735–6740.
[3]  Yasui W, Oue N, Aung PP, Matsumura S, Shutoh M, et al. (2005) Molecular-pathological prognostic factors of gastric cancer: a review. Gastric Cancer 8: 86–94.
[4]  Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, et al. (2001) Helicobacter pylori infection and the development of gastric cancer. New England Journal of Medicine 345: 784–789.
[5]  Houghton J, Stoicov C, Nomura S, Rogers AB, Carlson J, et al. (2004) Gastric cancer originating from bone marrow-derived cells. Science 306: 1568–1571.
[6]  Hiyama E, Yokoyama T, Tatsumoto N, Hiyama K, Imamura Y, et al. (1995) Telomerase activity in gastric cancer. Cancer research 15: 3258–3262.
[7]  Zheng L, Wang L, Ajani J, Xie K (2004) Molecular basis of gastric cancer development and progression. Gastric Cancer 7: 61–77.
[8]  Tahara E (2004) Genetic pathways of two types of gastric cancer. IARC scientific publications 157: 327–349.
[9]  Uefuji K, Ichikura T, Mochizuki H (2000) Cyclooxygenase-2 expression is related to prostaglandin biosynthesis and angiogenesis in human gastric cancer. Clinical cancer research 2000; 6: 135–138.
[10]  Wang Q, Wen YG, Li DP, Xia J, Zhou CZ, et al. (2012) Upregulated INHBA expression is associated with poor survival in gastric cancer. Medical Oncology 29: 77–83.
[11]  Carl-McGrath S, Lendeckel U, Ebert M, Roessner A, R?cken C (2005) Th disintegrin-metalloproteinases ADAM9, ADAM12, and ADAM15 are upregulated in gastric cancer. International journal of oncology 26: 17–24.
[12]  Xiao Q, Li L, Xie Y, Tan N, Wang C, et al. (2007) Transcription factor E2F-1 is upregulated in human gastric cancer tissues and its overexpression suppresses gastric tumor cell proliferation. Analytical Cellular Pathology 29: 335–349.
[13]  Yang YQ, Zhang LJ, Dong H, Jiang CL, Zhu ZG, et al. (2007) Upregulated expression of S100A6 in human gastric cancer. Journal of digestive diseases 8: 186–193.
[14]  Carl-McGrath S, Lendeckel U, Ebert M, Wolter AB, Roessner A, et al. (2004) The ectopeptidases CD10, CD13, CD26, and CD143 are upregulated in gastric cancer. International journal of oncology 25: 1223–1232.
[15]  Cheng YY, Jin H, Liu X, Siu JM, Wong YP, et al. (2008) Fibulin 1 is downregulated through promoter hypermethylation in gastric cancer. British journal of cance 99: 2083–2087.
[16]  Wang LJ, Jin HC, Wang X, Lam EK, Zhang JB, et al. (2009) ZIC1 is downregulated through promoter hypermethylation in gastric cancer. Biochemical and biophysical research communications 379: 959–963.
[17]  Liu Z, Wang X, Lu Y, Han S, Zhang F, et al. (2008) Expression of 15-PGDH is downregulated by COX-2 in gastric cancer. Carcinogenesis 29: 1219–1227.
[18]  Song HJ, Myung SJ, Kim IW, Jeong JY, Park YS, et al. (2011) 15-Hydroxyprostaglandin Dehydrogenase is Downregulated and Exhibits Tumor Suppressor Activity in Gastric Cancer. Cancer Investigation 29: 257–265.
[19]  Lewis BP, Burge CB, Bartel DP (2005) Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120: 15–20.
[20]  Lee Y, Ahn C, Han J, Choi H, Kim J, Yim J, et al. (2003) The nuclear RNase III Drosha initiates microRNA processing. Nature 425: 415–419.
[21]  Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, et al. (2005) MicroRNA expression profiles classify human cancers. Nature 435: 834–838.
[22]  Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, et al. (2006) Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 9: 189–198.
[23]  Ma L, Teruya-Feldstein J, Weinberg RA (2007) Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 449: 682–688.
[24]  Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL, et al. (2007) MicroRNA expression profiling in prostate cancer. Cancer research 67: 6130–6135.
[25]  Ji J, Shi J, Budhu A, Yu Z, Forgues M, et al. (2009) MicroRNA expression, survival, and response to interferon in liver cancer. New England Journal of Medicine 361: 1437–1447.
[26]  Akao Y, Nakagawa Y, Naoe T (2006) let-7 microRNA functions as a potential growth suppressor in human colon cancer cells. Biological & pharmaceutical bulletin 29: 903–906.
[27]  Kim , Yu , Han , Park , Namkoong , et al. (2009) Functional links between clustered microRNAs: suppression of cell-cycle inhibitors by microRNA clusters in gastric cancer. Nucleic acids research 37: 1672–1681.
[28]  Kim YK, Yu J, Han TS, Park SY, Namkoong B, et al. (2010) microRNA-22, downregulated in hepatocellular carcinoma and correlated with prognosis, suppresses cell proliferation and tumourigenicity. British journal of cancer 103: 1215–1220.
[29]  Friedman JM, Jones PA, Liang G (2009) The tumor suppressor microRNA-101 becomes an epigenetic player by targeting the polycomb group protein EZH2 in cancer. Cell cycle 8: 2313–2314.
[30]  Kefas B, Godlewski J, Comeau L, Li Y, Abounader R, et al. (2008) microRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma. Cancer research 68: 3566–3572.
[31]  Sun H, Li QW, Lv XY, Ai JZ, Yang QT, et al. (2010) MicroRNA-17 post-transcriptionally regulates polycystic kidney disease-2 gene and promotes cell proliferation. Molecular biology reports 37: 2951–2958.
[32]  Marquez RT, Wendlandt E, Galle CS, Keck K, McCaffrey AP (2010) MicroRNA-21 is upregulated during the proliferative phase of liver regeneration, targets Pellino-1, and inhibits NF-κB signaling. American Journal of Physiology-Gastrointestinal and Liver Physiology 298: G535–G541.
[33]  Lin RJ, Lin YC, Yu AL (2010) miR-149* induces apoptosis by inhibiting Akt1 and E2F1 in human cancer cells. Molecular carcinogenesis 49: 719–727.
[34]  Jin L, Hu WL, Jiang CC, Wang JX, Han CC, et al. (2011) MicroRNA-149*, a p53-responsive microRNA, functions as an oncogenic regulator in human melanoma. Proceedings of the National Academy of Sciences 108: 15840–15845.
[35]  Liu H, Brannon AR, Reddy AR, Alexe G, Seiler MW, et al. (2010) Identifying mRNA targets of microRNA dysregulated in cancer: with application to clear cell Renal Cell Carcinoma. BMC Systems Biology 27: 51–67.
[36]  Li D, Chen P, Li XY, Zhang LY, Xiong W, et al. (2011) Grade-Specific Expression Profiles of miRNAs/mRNAs and Docking Study in Human Grade I–III Astrocytomas. Omics: a journal of integrative biology 15: 673–682.
[37]  Schaefer A, Jung M, Mollenkopf HJ, Wagner I, Stephan C, et al. (2010) Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. International Journal of Cancer 126: 1166–1176.
[38]  Luo Z, Zhang L, Li Z, Li X, Li G, et al. (2012) An in silico analysis of dynamic changes in microRNA expression profiles in stepwise development of nasopharyngeal carcinoma. BMC Medical Genomics 19: 3–14.
[39]  Guglielmelli P, Tozzi L, Pancrazzi A, Bogani C, Antonioli E, et al. (2007) MicroRNA expression profile in granulocytes from primary myelofibrosis patients. Experimental hematology 11: 1708. e1–. e12.
[40]  Liu X, Wang T, Wakita T, Yang W (2010) Systematic identification of microRNA and messenger RNA profiles in hepatitis C virus-infected human hepatoma cells. Virology 398: 57–67.
[41]  Jeon BN, Choi WI, Yu MY, Yoon AR, Kim MH, et al. (2009) ZBTB2, a novel master regulator of the p53 pathway. Journal of Biological Chemistry 284: 17935–17946.
[42]  Hemmati PG, Gillissen B, von Haefen C, Wendt J, St?rck L, et al. (2002) Adenovirus-mediated overexpression of p14 (ARF) induces p53 and Bax-independent apoptosis. Oncogene 21: 3149–3161.
[43]  Lohrum MA, Ludwig RL, Kubbutat MH, Hanlon M, Vousden KH (2003) Regulation of HDM2 activity by the ribosomal protein L11. Cancer Cell 3: 577–587.
[44]  Harris SL, Levine AJ (2005) The p53 pathway: positive and negative feedback loops. Oncogene 24: 2899–2908.
[45]  Coqueret O (2003) New roles for p21 and p27 cell-cycle inhibitors: a function for each cell compartment? TRENDS in cell biology 13: 65–70.
[46]  Wu Q, Gou Y, Wang Q, Jin H, Cui L, et al. (2011) Downregulation of RPL6 by siRNA Inhibits Proliferation and Cell Cycle Progression of Human Gastric Cancer Cell Lines. PLoS One 6: e26401.

Full-Text

comments powered by Disqus